Insmed, Inc. (INSM): Price and Financial Metrics

Insmed, Inc. (INSM): $26.49

-0.41 (-1.52%)

POWR Rating

Component Grades













Add INSM to Watchlist
Sign Up

Industry: Biotech


of 504

in industry


  • INSM scores best on the Value dimension, with a Value rank ahead of 62.58% of US stocks.
  • INSM's strongest trending metric is Momentum; it's been moving down over the last 51 weeks.
  • INSM's current lowest rank is in the Momentum metric (where it is better than 4.42% of US stocks).

INSM Stock Summary

  • With a price/sales ratio of 18.17, INSMED Inc has a higher such ratio than 89.52% of stocks in our set.
  • With a year-over-year growth in debt of 48.8%, INSMED Inc's debt growth rate surpasses 86.21% of about US stocks.
  • INSMED Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -20.08%, greater than the shareholder yield of just 13.37% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to INSMED Inc, a group of peers worth examining would be INFN, GPL, RDUS, FBIO, and CDXS.
  • Visit INSM's SEC page to see the company's official filings. To visit the company's web site, go to

INSM Valuation Summary

  • In comparison to the median Healthcare stock, INSM's EV/EBIT ratio is 129.01% lower, now standing at -8.5.
  • Over the past 243 months, INSM's price/sales ratio has gone down 880.4.
  • Over the past 243 months, INSM's price/sales ratio has gone down 880.4.

Below are key valuation metrics over time for INSM.

Stock Date P/S P/B P/E EV/EBIT
INSM 2021-08-31 18.9 6.1 -8.6 -8.5
INSM 2021-08-30 18.7 6.0 -8.5 -8.4
INSM 2021-08-27 18.2 5.8 -8.3 -8.1
INSM 2021-08-26 17.4 5.6 -7.9 -7.8
INSM 2021-08-25 17.7 5.7 -8.1 -7.9
INSM 2021-08-24 17.2 5.5 -7.8 -7.6

INSM Growth Metrics

  • Its 5 year cash and equivalents growth rate is now at 51.64%.
  • Its 2 year net income to common stockholders growth rate is now at -10.18%.
  • The 4 year cash and equivalents growth rate now stands at 69.63%.
INSM's revenue has moved up $170,638,000 over the prior 33 months.

The table below shows INSM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 170.638 -329.185 -374.834
2021-03-31 167.767 -289.694 -319.367
2020-12-31 164.413 -219.348 -294.09
2020-09-30 168.706 -196.96 -244.865
2020-06-30 163.948 -190.66 -241.888
2020-03-31 151.425 -234.737 -246.548

INSM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INSM has a Quality Grade of C, ranking ahead of 33.6% of graded US stocks.
  • INSM's asset turnover comes in at 0.192 -- ranking 206th of 680 Pharmaceutical Products stocks.
  • SPPI, HSKA, and CYRX are the stocks whose asset turnover ratios are most correlated with INSM.

The table below shows INSM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.192 0.753 -0.585
2021-03-31 0.209 0.754 -0.551
2020-12-31 0.206 0.757 -0.513
2020-09-30 0.215 0.776 -0.415
2020-06-30 0.214 0.795 -0.422
2020-03-31 0.203 0.812 -0.452

INSM Price Target

For more insight on analysts targets of INSM, see our INSM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.78 Average Broker Recommendation 1.39 (Strong Buy)

INSM Stock Price Chart Interactive Chart >

Price chart for INSM

INSM Price/Volume Stats

Current price $26.49 52-week high $45.44
Prev. close $26.90 52-week low $22.00
Day low $26.44 Volume 640,400
Day high $27.38 Avg. volume 965,200
50-day MA $26.55 Dividend yield N/A
200-day MA $31.09 Market Cap 3.05B

Insmed, Inc. (INSM) Company Bio

Insmed Incorporated is a biopharmaceutical company focused on developing targeted inhaled therapies for patients suffering from rare lung diseases. The company was founded in 1999 and is based in Bridgewater, New Jersey.

INSM Latest News Stream

Event/Time News Detail
Loading, please wait...

INSM Latest Social Stream

Loading social stream, please wait...

View Full INSM Social Stream

Latest INSM News From Around the Web

Below are the latest news stories about INSMED Inc that investors may wish to consider to help them evaluate INSM as an investment opportunity.

Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2021 financial results on Thursday, October 28, 2021.

Yahoo | October 14, 2021

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

Yahoo | October 5, 2021

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 36% Undervalued

How far off is Insmed Incorporated ( NASDAQ:INSM ) from its intrinsic value? Using the most recent financial data...

Yahoo | September 10, 2021

Chief Compliance Officer Of Insmed Trades $730.57 Thousand In Company Stock

John Soriano, Chief Compliance Officer at Insmed (NASDAQ:INSM), made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that John Soriano purchased 17,349 Insmed shares at a price of $13.91 per share for a total of $241,325 on September 7. They then sold their shares on the same day in the open market. They sold at a price of $28.20 to raise a total of $489,242 from the stock

Yahoo | September 9, 2021

Insmed To Participate in Five September Conferences

Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events:

Yahoo | September 1, 2021

Read More 'INSM' Stories Here

INSM Price Returns

1-mo -1.08%
3-mo 3.07%
6-mo -17.99%
1-year -27.02%
3-year 55.55%
5-year 93.08%
YTD -20.43%
2020 39.41%
2019 82.01%
2018 -57.92%
2017 135.68%
2016 -27.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9441 seconds.